Ocrelizumab not recommended in France for patients with primary progressive multiple sclerosis while recommended in England : a review comparing the assessment by HAS and NICE
Date
2021-06-03
Journal Title
Journal ISSN
Volume Title
Publisher
Citation
Armoiry, X, Späth, H-M, Henaine , A-M, Dussart, C, Counsell, C & Connock, M 2021, 'Ocrelizumab not recommended in France for patients with primary progressive multiple sclerosis while recommended in England : a review comparing the assessment by HAS and NICE', Expert opinion on biological therapy, vol. 21, no. 6, pp. 741-747. https://doi.org/10.1080/14712598.2021.1865305